linjc16/ctgov huggingface dataset:
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in China

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the risk of congenital cytomegalovirus (cCMV) infection in newborns born to seropositive women.

Detailed Description
-----------------
This study will be conducted at several Maternal and Child Health Hospitals (MCHHs) in China and the research activities will be integrated with routine medical services during pregnancy at the study sites.The investigators will build a perspective cohort study enrolling  8000 pregnant women elder than 18 and following up their newborns at specific MCHHs.As a first step, The investigators will work with these hospitals to recruit the subjects. After being informed, the participants' remaining blood and urine samples (after their medical examinations) at their early, medium and late stages of pregnancy will be collected , and their newborns' urine and saliva samples will be collected after delivery. The aim of this study is to enroll 5000 series mother-newborns.

Official Title
-----------------
A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Neonates in China

Conditions
-----------------
Congenital Cytomegalovirus Infection, Cytomegalovirus Infection Reactivation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females aged 18 and older Pregnancy confirmed by ultrasound Come to MCHHs for Pregnancy Registry within 24 weeks of pregnancy Exclusion Criteria: Not capable of complying with study procedures, or having a psychosis, two-stage affective psychosis, or have a tendency to suicide Having any autoimmune diseases (include systemic lupus erythematosus, rheumatoid arthritis), immunodeficiency (e.g. AIDS), chronic disease history such as cancers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cCMV infection in newborns born to CMV seropositive pregnant women. |  | up to 45 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cCMV infection in newborns to pregnant women with different maternal PP150-IgG titers in the early pregnancy. |  | up to 45 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytomegalovirus
Dysphagia Symptom Severity and Quality of Life

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to investigate the relationship between dysphagia symptom severity and quality of life of the patients with neurogenic dysphagia.

Detailed Description
-----------------
The dysphagia related quality of life and perceived dysphagia symptom severity by patients will be used as a complementary information on oropharyngeal dysphagia. Thus, the aim of the study is to investigate the relationship between dysphagia symptom severity and quality of life of the patients with neurogenic dysphagia.

Official Title
-----------------
The Relationship Between Dysphagia Symptom Severity and Quality of Life

Conditions
-----------------
Neurogenic Dysphagia

Intervention / Treatment
-----------------
* Other: Dysphagia evaluation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to participate in the study Being over the age of 20 Normal cognitive function Suffering from dysphagia at least one month Exclusion Criteria: Being under the age of 20 and above 65 years. Abnormal cognitive function Clinically unstable neurological disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurogenic dysphagia<br>Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed. | Other: Dysphagia evaluation<br>* Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dysphagia symptom severity | Dysphagia symptom severity will be determined by an eating assessment tool. | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life | Swallowing related quality of life will be determined by an dysphagia specific quality of life instrument called Swallow Quality of Life. | 1 month |
Effect of Sevoflurane, Propofol and Dexmedetomidine on Delirium & Neuroinflammation in Mechanically Ventilated Patients

Study Overview
=================
Brief Summary
-----------------
Assessment of sedative effects of sevoflurane, dexmedetomidine and propofol on the clinical course of delirium, SIRS and neuroinflammation in mechanically ventilated patients using CAM-ICU scale, GSK-3beta and protein S100b in serum.

Official Title
-----------------
Comparison of Sedative Effects of Sevoflurane, Propofol and Dexmedetomidine on the Clinical Course of Delirium and Neuroinflammation in Mechanically Ventilated Patients

Conditions
-----------------
Delirium

Intervention / Treatment
-----------------
* Drug: Sevoflurane
* Drug: Propofol
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of delirium Exclusion Criteria: presence of Alzheimer's disease any mental disorder presence of cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Sevoflurane<br>Treatment of delirium by inhaled sevoflurane | Drug: Sevoflurane<br>* Treatment of delirium by inhaled sevoflurane<br>* Other names: Sevorane;|
| Active Comparator: Propofol<br>Treatment of delirium by propofol i.v. infusion | Drug: Propofol<br>* Treatment of delirium by propofol i.v. infusion<br>* Other names: Diprivan;|
| Active Comparator: Dexmedetomidine<br>Treatment of delirium by dexmedetomidine i.v. infusion | Drug: Dexmedetomidine<br>* Treatment of delirium by dexmedetomidine i.v. infusion<br>* Other names: Dexdor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Delirium | Delirium assessment by CAM-ICU scale | up to 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of protein S100b in serum |  | from delirium onset up to 5 days | 
| Change of GSK-3beta in serum |  | from delirium onset up to 5 days |
Effective Adjunctive Use of Pergolide for Cognitive Impairment and Negative Symptoms in Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Dopamine has been closely associated with prefrontal function. The hypothesis that a lower dopaminergic activity is associated with negative symptoms and cognitive dysfunction observed in the patients of schizophrenia is of a heuristic value in guiding research in this area. This hypothesis led us to test whether pergolide, a D1/D2 agonist, could improve negative symptoms and cognitive impairments prevailing in most patients with schizophrenia. This double-blind placebo controlled study will investigate the remedial effect of pergolide on negative symptoms and cognitive impairments in schizophrenia.

Official Title
-----------------
Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia

Conditions
-----------------
Schizophrenia, Negative Symptoms, Cognitive Impairments

Intervention / Treatment
-----------------
* Drug: Pergolide (drug)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients Were age 18-50 years, met the DSM-IV criteria for schizophrenia Were treated with a stable dose of risperidone, raging 2 to 6mg, for more than 8 weeks Had a score ≥15 on negative subscale items in Positive and Negative Syndrome Scale (PANSS) Had a minimum period of symptom stability, defined as no more than 20% change on consecutive ratings on PANSS for at lease 4 weeks Exclusion Criteria: Had a history of medical condition or drug treatment that may have affected cognitive performance Had a history of other psychiatric disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pergolide (drug)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pergolide, Dopamine D1, Schizophrenia, Cognitive disturbance, Negative symptoms
Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

Study Overview
=================
Brief Summary
-----------------
Delinieation of GIP's effects during a meal in humans using GIP receptor antagonisation.

Detailed Description
-----------------
Aim: To evaluate the role of GIPR signalling in postprandial physiology, including lipid, bone and glucose homeostasis, using a naturally occurring GIP fragment, which antagonises the GIPR. Twelve healthy men (age 18-70 years, BMI 19-27 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).

Official Title
-----------------
Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

Conditions
-----------------
Glucose Metabolism Disorders

Intervention / Treatment
-----------------
* Other: GIP-A
* Other: Placebo
* Other: GLP-1 receptor antagonist Exendin[9-39]
* Other: GIP-A + Exendin[9-39]


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal kidney function, liver function and hemoglobin levels. Exclusion Criteria: Medication, Diabetes type 1 or 2, BMI > 27, first degree relatives with Type 2 Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Saline | Other: Placebo<br>* Placebo<br>|
| Other: GIP-A<br>Infusion of GIP-A alone as study tool. | Other: GIP-A<br>* GIP-A<br>|
| Other: GLP-1 receptor antagonist Exendin[9-39]<br>Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool. | Other: GLP-1 receptor antagonist Exendin[9-39]<br>* Exendin[9-39]<br>* Other names: Ex(9-39);|
| Other: GIP-A + Exendin[9-39]<br>Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools. | Other: GIP-A + Exendin[9-39]<br>* GIP-A + Exendin[9-39]<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| C-peptide levels | Serum C-peptide AUC. Primary outcome changed during the inclusion period (original = insulin levels) due to risk of misinterpretation/diverse hepatic insulin extraction). | 180 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GIP, GIP receptor antagonist
Prediction of Extubation Failure: A Multicenter Prospective Observational Study

Study Overview
=================
Brief Summary
-----------------
The investigators intend to collect several variables to predict extubation failure among patients who successfully complete a spontaneous breathing trial, and then develop a scale using simple bedside indicators to predict extubation failure.

Detailed Description
-----------------
Mechanically ventilated patients who successfully completed a spontaneous breathing trial and prepared for extubation are eligible to enroll in this study. The vital signs, arterial blood gas tests, cough strength, cuff leak test, use of noninvasive ventilation et al. are collected. Patients are followed up to postextubation 28-day or discharge. Extubation failure is defined as reintubatin or death within postextubation 7 days. First, we will analyze the data to predict extubation failure. Then, we will combine several easily obtained variables to develop and validate a scale to predict extubation failure. Finally, we explore the predictive power of extubation failure tested by the scale and find the cutoff value to distinguish the low, moderate and high risk of extubation failure.

Official Title
-----------------
The First Affiliated Hospital of Chongqing Medical University

Conditions
-----------------
Mechanical Ventilation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Prepared for extubation through spontaneous breathing trial;Oral or nasal endotracheal intubation; be at least 18 years old Exclusion Criteria: Extubation without a spontaneous breathing trial ;Reintubation due to secondary surgery; Tracheotomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with extubation after a weaning trial<br>Patients who sucessfully complete a spontaneous breathing trial are enrolled in this group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of extubation failure | Extubation failure was defined as the reintubation or death | From extubation to 48 hours | 
| Rate of extubation failure | Extubation failure was defined as the reintubation or death | From extubation to 7 days | 
| Rate of extubation failure | Extubation failure was defined as the reintubation or death | From extubation to 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of mortality | Mortality in ICU and hospital | From extubation to 28 days | 
| ICU stay | Length of ICU stay | From extubation to 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Extubation Failure
Sympathetic Nerve Activity and an Implantable Cardioverter Defibrillator in Heart Failure Patients

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to analyze whether the sympathetic tone, measured indirectly and directly by muscle sympathetic nerve activity recording, is elevated in patients with heart failure receiving an appropriate shock from their implantable cardiac defibrillator (ICD) compared to heart failure patients not receiving a shock from their ICD. All parameters measured in this study will be used to build a risk algorithm able to identify heart failure patients at high risk for sudden cardiac death who could receive an ICD.

Detailed Description
-----------------
We plan to perform an extensive study of the sympathetic nervous system activity in heart failure patients with an ICD. The SNS activity will be measured directly by a recording of the muscle sympathetic nerve activity and indirectly by post processing of 24-hour Holter recording, catecholamine levels assessment, and spontaneous baroreflex sensitivity. A global assessment of the patients status will also be realised. Patients will be followed for one year. During follow up, this cohort will be divided into two groups according to the occurrence or not of an appropriate shock. We assume that an appropriate shock is a surrogate marker for sudden cardiac death. We plan to compare the autonomic nervous system activity in both groups of patients in order to identify a score able to detect heart failure patients at high risk for sudden cardiac death.

Official Title
-----------------
Validation of a Prognostic Score to Identify Heart Failure Patients Who Might Need an Implantable Cardioverter Defibrillator Using Muscle Sympathetic Nerve Activity and Autonomic Testing

Conditions
-----------------
Heart Failure, Death, Sudden, Cardiac

Intervention / Treatment
-----------------
* Procedure: Microneurography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heart failure patient with an ICD Exclusion Criteria: Pregnant patient Acute coronary syndrome within the last 3 months Peripheral neuropathy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Microneurography|Microneurography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
implantable cardioverter defibrillator, Heart failure, Sudden Cardiac Arrest, appropriate shock, Defibrillators, Implantable
Comparison of Electric Heating Pad Versus Forced-air Warming to Prevent Inadvertent Perioperative Hypothermia

Study Overview
=================
Brief Summary
-----------------
Compare core body temperature after laparoscopic surgery using the forced air heating system versus the WARMTAC® (a carbon fiber electric blanket).

Detailed Description
-----------------
In order to prevent perioperative hypothermia, we will compare two different heating sistems, one of them is an electric pad made with carbon fiber and the other system is a forced-air blanket. Both of them will be situated under the patient during all the laparoscopic surgey.

Official Title
-----------------
Comparison of Electric Heating Pad Versus Forced-air Warming to Prevent Inadvertent Perioperative Hypothermia: A Randomized Controlled Trial

Conditions
-----------------
Temperature Change, Body, Hypothermia; Anesthesia

Intervention / Treatment
-----------------
* Device: WARMTAC
* Device: 3M Bair Hugger


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years of age at the time of the preoperative visit. Patients who will undergo elective laparoscopic surgery Patients who sign the informed consent indicating that they have been informed of all relevant aspects of the trial. Exclusion Criteria: Axillary temperature> 37.5ºC Active infection Dysfunction of the autonomic system

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Electrical heating pad<br>Electrical heating pad (WARMTAC device). Patients will be randomized to one arm. In this arm, the WARMTAC device will be conected and warmed to 41 degrees before patients lay down. | Device: WARMTAC<br>* Randomization to one of the arms previous to surgery.<br>|
| Experimental: forced-air warming device<br>Forced-air warming device (3M device). In this arm, the 3M blanket will be conected to forced-air machine and warmed to 41 degrees before patients lay down. | Device: 3M Bair Hugger<br>* Randomization to one of the arms previous to surgery.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Core body temperature | temperatured recorded in esophagus | through study completion, an average of 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rescues number | Compare number of rescues required by each system to avoid mild hypothermia | through study completion, an average of 12 months | 
| skin lesions | Detect possible skin complications related to heating | through study completion, an average of 12 months |